Home › Funds › Fairmount Funds Management LLC › DMRA
Fairmount Funds Management LLC position in DMRA
DAMORA THERAPEUTICS INC COM SHS · Health Care
Fairmount Funds Management LLC reported holding 8,713,000 shares of DMRA (DAMORA THERAPEUTICS INC COM SHS) in its Q2 2026 13F filing — a position valued at US$226.6M, representing 14.98% of its reported portfolio and ranking #3 among its reported holdings. Fairmount Funds Management LLC has disclosed DMRA holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Fairmount Funds Management LLC's DMRA position evolved
Fairmount Funds Management LLC first disclosed a stake in DMRA in Q1 2026 at 8,713,000 shares (US$225.7M). The position peaked in Q2 2026 at 8,713,000 shares, worth US$226.6M. Across 2 filings, Fairmount Funds Management LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 8,713,000 shares valued at US$226.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 8.71M | $225.67M | New |
| Q2 2026 | 8.71M | $226.63M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DMRA and 13F data
DMRA (DAMORA THERAPEUTICS INC COM SHS) is a Health Care company. 105 other funds we track also report a position in DMRA — the largest reported positions include Avoro Capital Advisors LLC (US$98.4M), Venrock Adviser, LLC (US$93.7M), FCPM III SERVICES B.V. (US$63.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DMRA
- Avoro Capital Advisors LLC 3.78M sh · $98.40M · Q2 2026
- Venrock Adviser, LLC 3.60M sh · $93.73M · Q2 2026
- FCPM III SERVICES B.V. 2.44M sh · $63.49M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.40M sh · $62.42M · Q2 2026
- Remedium Capital Partners, LLC 2.05M sh · $53.20M · Q2 2026
- Commodore Capital LP 1.94M sh · $50.43M · Q2 2026
- BRAIDWELL LP 1.62M sh · $42.15M · Q2 2026
- Bellevue Group AG 1.62M sh · $42.11M · Q2 2026
- a16z Capital Management, L.L.C. 1.24M sh · $32.15M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.22M sh · $31.81M · Q2 2026
- Cormorant Asset Management, LP 1.00M sh · $26.01M · Q2 2026
- Vestal Point Capital, LP 575.00K sh · $14.96M · Q2 2026
More on Fairmount Funds Management LLC
FAQ
How long has Fairmount Funds Management LLC held DMRA?
Fairmount Funds Management LLC has disclosed DMRA holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Fairmount Funds Management LLC's current position in DMRA?
As of Q2 2026, Fairmount Funds Management LLC holds 8.71M shares of DMRA (DAMORA THERAPEUTICS INC COM SHS), valued at $226.63M, representing 14.98% of its reported portfolio and ranking #3.
Has Fairmount Funds Management LLC been buying or selling DMRA?
In the latest 13F filing (Q2 2026), Fairmount Funds Management LLC held unchanged its position in DMRA. The position peaked in Q2 2026 at 8.71M shares.
Which other funds hold DMRA?
Other major institutional holders of DMRA include Avoro Capital Advisors LLC, Venrock Adviser, LLC, FCPM III SERVICES B.V., among 105 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.